Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Gatiflo eye drops launched in Japan

Sep. 8, 2004

Macugen NDA accepted for review

Aug. 23, 2004

Pfizer scientists describe new antiangiogenic agents for ocular disorders

Aug. 19, 2004

Acuity files IND for phase I trials of Cand5

Aug. 16, 2004

Approvable letter for ZyLET

Aug. 11, 2004

Hybridon licenses VEGF rights to Alnylam for ocular indications

Aug. 10, 2004

Ista submits sNDA for Vitrase as spreading agent

Aug. 10, 2004

Approvable letter for Lumigan-timolol combination

Aug. 5, 2004

Alcon patent covers new 5-HT2 agonists for glaucoma therapy

Aug. 5, 2004

ISTA launches Istalol for glaucoma

Aug. 2, 2004

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...